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ABSTRACT
Hot melt extrusion (HME) is a leading technology that can be applied to many
pharmaceutical preparations as solid dispersions. Part of this research project focus on
injecting pressurized carbon dioxide (P-CO2) gas during the HME process. These
combined techniques have an additional advantage of being adaptable and portable to a
hot melt extruder instrument. The use of HME alongside with other techniques (P-CO2 or
co extrusion process) for preparing an improved controlled/sustained release formulation
is the main theme of this research project. Current research focusing on Active
Pharmaceutical Ingredients (APIs) with good aqueous solubility requires novel approach
to obtain tailored drug release for the processed sustained/controlled release formulations.
HME, when combined with other novel techniques has been shown to be a practicable
method for the development of novel floating drug delivery systems. This research also
focused on the feasibility of HME/P-CO2 and HME/co extrusion techniques to prepare
the intended formulation with specific properties with detailed explanation of the
resulting dosage forms. Also, it explores the effects of different formulation variables and
process parameters on the quality of final product. These studies of research facilitate the
development of floating drug delivery devices, as well as improving the consistency of
the powder flow while processing which result in with improved drug content with
comparable sustained release profile to the marketed formulation.
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The key objectives of this dissertation chapters are: (1) to introduce HME as an efficient
technique alongside when combined with other novel techniques in pharmaceutical
industry; (2) to prepare floating mini tablets of acetaminophen (APAP) with the
hydrophobic carriers Eudragit® RL PO and Eudragit® RS PO by HME/P-CO2 and to
evaluate the buoyancy efficiency through in-vitro methods. Moreover, scanning electron
microscopy (SEM) was utilized to visually investigate the morphological change of the
matrix; (3) to develop of sustained-released donepezil hydrochloride (DH) formulations
with various hydrophobic carriers utilizing HME technique alone to optimize hot melt
process parameters for obtaining the desirable sustained release profile ; (4) to develop
and evaluate a sustained-release DH formulation with improved & consistent drug
content and tablet content uniformity via co extrusion tablet filler through the extruder.
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CHAPTER 1: INTRODUCTION
BREIF OVERVIEW
Hot-melt extrusion (HME) is not only commonly used technology in the plastic,
rubber and food industry but also it has wide array of application in the pharmaceutical
industry. HME is one of the most efficient technology to prepare solid dispersions. In
HME process, the Active Pharmaceutical Ingredient (API) and the carrier matrix can be
mixed/blended together to prepare a physical mixture that can be extruded under certain
specific conditions as a feasible and continuous process (Patil, Tiwari, & Repka, 2015;
Shah, Maddineni, Lu, & Repka, 2013a). The processing parameters such as feeding rate,
shearing force, temperature, die geometry, barrel design, screw rotating speed should be
considered as it may contribute significantly in the quality of the final product such as
uniformity of size, shape and content. HME offers several advantages over other
conventional methods for example, it is one-step solvent-free, giving a continuous
operation, which has fewer processing steps, requires no compression and can improve
bioavailability due to dispersion of the drug at the molecular level. However, there are
few limitations which could restrict the use of HME in the pharmaceutical industry, for
instance, it requires a higher energy input compared to other techniques and may exclude
some thermo-labile compounds due to high processing temperatures (Crowley et al.,
2007; M. A. Repka et al., 2007).
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The popularity of the HME as a pharmaceutical technology has been increasing day
by day and this is evidenced by increased number of worldwide patents issued,
commercial pharmaceutical products and available research articles. It has been
successfully used to prepare various pharmaceutical drug delivery systems such as pellets
(Alshetaili et al., 2016), granules (J. Liu, Zhang, & McGinity, 2001), immediate and
modified release tablets (Patil, Tiwari, Upadhye, Vladyka, & Repka, 2015), taste-masked
oral fast dissolving systems (Alshehri et al., 2015), transdermal delivery systems (M a
Repka, Gerding, Repka, & McGinity, 1999), transungual delivery systems (Mididoddi &
Repka, 2007), solid lipid nanoparticle systems (Patil, Feng, Ye, Majumdar, & Repka,
2014; Patil, Kulkarni, Majumdar, & Repka, 2014), nanocrystals (Khinast, Baumgartner,
& Roblegg, 2013; Ye et al., 2015), and floating drug delivery systems (Bjad K.
Almutairy et al., 2015; Fukuda, Peppas, & McGinity, 2006a). Floating drug delivery
systems is one of the themes of this dissertation. These systems are utilized to increase
the residence time of APIs within stomach. Increasing the gastric residence time of any
dosage form can be achieved by recent approaches which include bio-adhesive systems
that are increased in size upon swallowing, and low-density systems that float on the
gastric fluids. To prolong the dosage form residence time, one of the following
approaches is used: swelling system expanding systems, floating drug delivery systems,
which also known as hydrodynamically balanced systems, bio-adhesive systems, highdensity systems, and delayed gastric emptying devices. The reason why we chose multi
particulate system/multi units’ system is being helpful for fixed dose formulation that has
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more than one API.

EQUIPMENT
An extruder consists of a feeder, barrel with screws or ram, control panel, torque
sensors, heating/cooling device, with dies. On-line and in-line quality control analysis
using near-infrared (NIR) probe and other well-known analysis like Raman, ultrasonic
and dielectric spectroscopy can be easily adapted with HME process (Alig, Fischer,
Lellinger, & Steinhoff, 2005). Pharmaceutical screw extruders are designed based upon
the regulatory guidelines to produce desired extrudates (shape and size). There are mainly
three types of extruders: 1) single-screw extruder, 2) twin screw extruder and 3) multiple
screw extruder. Among these types, twin screw extruder has been used widely in the
pharmaceutical research and industry. There are two types of twin screw extruders. First
one is high-speed energy input (HSEI) twin-screw extruder, which is mainly used for
compounding, reactive processing and/or devolatilization. The second one is low-speed
late fusion (LSLF) twin-screw extruders, which is designed to mix at low shear and pump
at uniform pressures. Twin-screw extruder has many advantages over single-screw
extruder as it overcomes formulation mixing problem and provides complete mixing of
the components. For higher capacity extruders, each zone has independent
heating/cooling units and temperature sensors that can efficiently maintain the individual
zones at preset temperatures. In addition, pressure arises due to the friction of the material
inside the barrel and the resistance exerted by the material against the barrel walls assists
the ejection of material through the die. The two screws can be oriented in a number of
3

configurations depending on the desired level of shear and speed of operation. These
configurations setting can play a significant role in addressing some issue related to the
formulation. For example, Morott et al. concluded that the screw configuration is a
dependent parameter in the efficiency and stability of some taste-masked formulations.
Through specific screw configuration, they have demonstrated that sildenafil citrate’s
crystallinity can be preserved with successfully processed formulations (Morott et al.,
2015). In addition, Teixeira et al. have investigated algorithmic tools that are effective
and required by industry. They determined the appropriate and adapted screw
configurations for specific aims (Teixeira, Covas, Stützle, & Gaspar-Cunha, 2012).
Depending to the required intensity of mixing, the two screws can be designed to rotate in
the same direction (co-rotating) or in the opposite direction (counter-rotating). The
counter-rotating designs are utilized when very high shear regions are needed as they
impose materials to very high shear forces as the material is squeezed through the gap
between the two screws as they come together. However, co-rotating screws are mainly
used in pharmaceutical manufacturing (Crowley et al., 2007).

DOWNSTREAM PROCESSING EQUIPMENT
Many formulations can be processed using melt extrusion technology. Scientists
have many options for the selection of the preferring specific die shapes and sizes. Flat
dies are used for production of films (M a Repka et al., 1999; Michael a Repka,
Prodduturi, & Stodghill, 2003; Trey, Wicks, Mididoddi, & Repka, 2007) and patches
(Palem et al., 2013), whereas circular dies are used for palletization and spheronization
4

(Alshetaili et al., 2016; R. V Tiwari, Patil, & Repka, 2016; Young, Koleng, & McGinity,
2002). The molten drug-polymer mixture can also be filled into molds using injection
molding. For instance, these molds can be formed to yield the tablet, capsule shapes, ear
inserts or designed pediatric formulation (Patil, Tiwari, & Repka, 2015; Michael a Repka
et al., 2012). Some of the dosage forms that have been studied previously are rods, film
(M a Repka et al., 1999), pellets, spherical pellets (Alshetaili et al., 2016; Young et al.,
2002), punched tablets (Andrews et al., 2008; Verreck et al., 2005), injection molded
tablets (Quinten et al., 2009), and granules (Mishra, 2016; Robinson & McGinity, 2000).

GENERAL ASPECTS
HME processing parameters and addressing related mixing issues
From the general understanding of the processing, HME can be theoretically divided
into five steps: i) feeding, ii) melting and plasticizing, iii) conveying and mixing, iv)
venting and v) stripping and downstream processing. Each section may affect the
properties of the final extrudates. These affected properties might arise an issue in the
process, which needs to be fixed during the optimization stage. The material to be
extruded is introduced into the feed section of extruder via a hopper. It is essential that
the angle of the feed hopper is always exceeding the angle of repose of the feed material
in order to assure good flow properties of the feedstock. Otherwise, there will be an
arising issue, as the material tends to form a solid bridge at the neck of the hopper
resulting in changeable flow. However, to address this issue, a force-feeding device such
as a mass flow feeder or side stuffer can be used to run the feedstock onto the rotating
5

screw. Mixing is a potential factor during HME process and is classified as distributive
mixing and dispersive mixing. Processing parameters play a key role in determining the
properties of the extrudates. Some of the most commonly adjusted parameters include
screw speed, processing temperature and feeding rate. The screw speed and feeding rate
are also related to shear stress, shear rate and mean residence time, which will affect the
dissolution rate and stability of the final products (Crowley et al., 2007; Mishra, 2016; R.
V Tiwari et al., 2016).

Screw design and configuration
The design and configuration of the screw have a significant impact on the process
and can be selected to meet particular requirements such as high or low shear. Screws are
designed with several sections, with the function of each section ranging from feeding,
mixing, compression, and metering. To improve the melting process and mass flow
through the extruder, modulating the screw design is sometimes potential factor (Morott
et al., 2015). The efficiency of the melting process is highly dependent on the polymer’s
properties and the extruder design. However, very few articles in the literature discuss the
effects of screw design and configuration on HME processing. Morott et al. demonstrated
that the screw configuration has an influence on the quality of the products when using a
twin-screw extruder. Kneading paddle elements of the twin-screw extruder is another
example. Nakamichi et al. demonstrated that they played an important role in changing
the crystallinity and dissolution properties of a solid dispersion of kneaded nifedipinehydroxy propyl methyl cellulose phthalate (Nakamichi, Nakano, Yasuura, Izumi, &
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Kawashima, 2002). Verhoeven et al. described that the distribution homogeneity and the
release rate of metoprolol tartrate in ethyl cellulose mini-matrices were not significantly
affected by the number of kneading mixing zones or their positions along the extruder
barrel and that at least one kneading/mixing zone was required for homogenous
distribution (Verhoeven, De Beer, Van den Mooter, Remon, & Vervaet, 2008). Liu et al.
studied the effects of screw configuration on the dissolution behavior of indomethacin in
Eudragit EPO melt extrudate. Further, they identified that the kneading blocks
accelerated the complete dissolution process of indomethacin in polymer melt (H. Liu,
Wang, Zhang, Shen, & Gogos, 2010). Thus, from the above-mentioned reports, it is clear
and evident that HME processing parameters plays an important role in determining the
properties of the extrudates.

Process analytical technology (PAT) and scale up issues
PAT can be used as a tool to monitor, closely observe, analyze, and characterize melt
extrusion and chemical composition of the products in line to ensure final desired product
attributes. Using PAT as an analytical tool, flow properties, polymer structures, polymerdrug interaction as well as concentrations of drugs and additives can be determined
immediately downstream of the extrusion process (Alig et al., 2005). Scaling-up in HME
like other manufacturing technologies is an important subject of discussion. For scale up,
the aspect of autogenous extrusion is also important since the ratio of surface to volume
become more unfavorable with increasing extruder size, especially if the process has not
been developed to run autogenously on a small scale. Increasing in the size of the
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extruder can cause some issues such as variation in the ratio of surface to volume. As it is
deliberated that extruder is aimed to be as closed system as a pipe with forced conveying
by the extruder screw, the mean residence time can be as short as less than 30 seconds.
The impact of process parameter on the residence time and torque should be known for
each formulation to the respective extruder. This allows us for making better comparison
and understanding the correlation (Maniruzzaman & Nokhodchi, 2016).

Co-extrusion process
This co-extrusion process solves the issues related with material impaired by individual
extruded polymer layer. The process of extruding two or more materials through a single
die with two or more orifices arranged so that the extrudates merge and join together into
a laminar structure before chilling is called co-extrusion. The physical mixture is fed
through the hopper to the extruder (separately), however the orifices is arranged in such a
way that the material will be extruded through a common die thus creating a bilayer
(Iosio et al., 2008) or multilayer end product (Mofidfar et al., 2016; Wang et al., 2014).
An example for bilayer end product is the work that has been done by Iosio et al. (Iosio et
al., 2008). The compositions of those two layers are microcrystalline cellulose, lactose
and water along with wetted with the self-emulsifying system. Regarding multilayer, the
final product obtained may be in the form of a laminar structure with multiple layers,
which may offer several advantages due to material and composition characteristics
imparted by the individual extruded polymer layer. The principle of co-extrusion shows
promise for many novel dosage forms, including oral, transdermal and implants (Dierickx
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et al., 2012, 2014; Quintavalle et al., 2008; Quintavalle, Voinovich, Perissutti, Serdoz, &
Grassi, 2007; R. V Tiwari et al., 2016; Vynckier et al., 2014; Vynckier, Voorspoels,
Remon, & Vervaet, 2016).

Use of plasticizers as processing aids
Use of plasticizer into the formulations would aid to improve the processing
conditions during the manufacturing of the extruded dosage form or to improve the
physical and mechanical properties of the final product. Examples are triacetin, citrate
esters, D-a-tocopheryl, and surfactants. Moreover, injection of pressurized CO 2 during
HME processing shows a reduction in processing temperatures of variety of polymers in
producing extruded dosage form. In addition, pressurized CO 2 acts as a foaming agent
(Ashour et al., 2015). It has also been shown that CO 2 acts as a plasticizer for PVP-VA
64, Eudragit® E100 and Ethyl Cellulose 20 cps, allowing for a reduction in processing
temperature(Verreck et al., 2006). Additionally, several drug substances have been
reported to function as plasticizers in hot-melt extruded dosage forms. Repka et al (M a
Repka et al., 1999) have studied the effect of chlorpheniramine maleate and
hydrocortisone as plasticizers for hydroxy propyl cellulose films. These two APIs (1%)
have shown a plasticizing property on that specific polymer. In addition, they provide
mechanical stability to the films. Employing this technique has substantial effect in
transdermal films. It gives a broader flexibility to films by the effect on polymer matrix.
Some APIs have been utilized by their own plasticizing effect. For instance, Ibuprofen
has been used in HME as a plasticizer in some formulations(De Brabander, Van Den
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Mooter, Vervaet, & Remon, 2002). In addition, vitamin E TPGS has been utilized as an
excellent processing aid It has been employed to successfully produce plasticized
matrices (M. A. Repka & McGinity, 2000).

Other processing aids
Hydroxy propyl cellulose (HPC) or ethyl cellulose (EC) may encounter oxidation
effect when they expose to higher temperatures. Incorporation of an antioxidant, such as
butylated hydroxytoluene or ascorbic acid, into these formulations is highly
recommended. Similarly, a combination of an antioxidant, light absorber and acid
acceptor is recommended for systems using EC. PEO films have been reported to be
protected from free radical and oxidative degradation by the incorporation of an
antioxidant (Mishra, 2016; M. A. Repka et al., 2007; R. V Tiwari et al., 2016).
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CHAPTER 2:
DEVELOPMENT OF FLOATING DRUG DELIVERY SYSTEM WITH SUPERIOR
BUOYANCY IN GASTRIC FLUID USING HOT-MELT EXTRUSION COUPLED
WITH PRESSURIZED CO2
ABSTRACT
The present study aimed to develop a continuous single-step manufacturing platform to
prepare a porous, low-density, and floating multi-particulate system (mini-tablet, 4 mm
size). This process involves injecting inert, non-toxic pressurized CO2 gas (P-CO2) in
zone 4 of a 16-mm hot-melt extruder (HME) to continuously generate pores throughout
the carrier matrix. Unlike conventional methods for preparing floating drug delivery
systems, additional chemical excipients and additives are not needed in this approach to
create minute openings on the surface of the matrices. The buoyancy efficiency of the
prepared floating system (injection of P-CO2) in terms of lag time (0 sec) significantly
improved (P < 0.05), compared to the formulation prepared by adding the excipient
sodium bicarbonate (lag time 120 sec). The main advantages of this novel manufacturing
technique include: (i) no additional chemical excipients need to be incorporated in the
formulation, (ii) few manufacturing steps are required, (iii) high buoyancy efficiency is
attained, and (iv) the extrudate is free of toxic solvent residues. Floating mini-tablets
containing acetaminophen (APAP) as a model drug within the matrix-forming carrier
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(Eudragit® RL PO) have been successfully processed via this combined technique (PCO2/HME). Desired controlled release profile of APAP from the polymer Eudragit ® RL
PO is attained in the optimized formulation, which remains buoyant on the surface of
gastric fluids prior to gastric emptying time (average each 4 h).

Keywords: Hot-Melt Extrusion, Pressurized CO2, Floating tablet, Acetaminophen,
Eudragit® RL PO.

2.1. Introduction
Hot-melt extrusion (HME) is a leading technology for the manufacture of solid
dispersions using polymers as matrix-forming carriers; various solid dosage forms can be
manufactured using this process (Alshehri et al., 2015; Patil, Feng, et al., 2014; M. A.
Repka et al., 2007). One of those solid dosage forms is that of a low-density based
floating system (A. Streubel, Siepmann, & Bodmeier, 2002). Floating drug delivery
systems developed by the pharmaceutical industry specialists are readily available (B. N.
Singh & Kim, 2000). The advent of innovative techniques has ushered scientists into an
era of increasingly productive and cost-effective manufacturing processes. In order to
address the common limitations of conventional methods and to overcome the difficulties
in formulating floating systems using these methods (Table 2-1) (Badawy & Hussain,
2007; Fordtran, Morawski, Santa Ana, & Rector Jr., 1984; Forslund, Koistinen, Anttinen,
Wagner, & Miettinen, 2008; Fukuda, Peppas, & McGinity, 2006b; Thomas & Stone,
1994), a novel-manufacturing platform has been proposed and was compared with the
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latest technique for manufacturing Floating Drug Delivery Systems (FDDS) (Patil,
Tiwari, & Repka, 2015).
Not only has HME gained increasing attention among industrial pharmacy researchers,
recently, injecting pressurized carbon dioxide (P-CO2) gas during the HME process has
also received much attention. Injecting P-CO2 gas during a solvent-free continuous HME
process has an added advantage of being adaptable and portable to a hot melt extruder
instrument (A. Ashour et al., 2015).
Most of the conventional methods for preparing floating systems, such as the
microsphere and gel formation floating method, depend on the use of organic solvents
such as n-hexane, ethanol, methanol etc. (Choi, Park, Hwang, & Park, 2002; Dhaliwal,
Jain, Singh, & Tiwary, 2008; Galeska et al., 2005; Silva, Ribeiro, Figueiredo, Ferreira, &
Veiga, 2005; Thanoo, Sunny, & Jayakrishnan, 1993). The residual of these solvents can
be hazardous to health upon long-term use. Another approach utilizes lipids as lowdensity floating devices; however, instability and polymorphism of crystalline lipid
matrices limits the use of these agents (Chauhan, Shimpi, Mahadik, & Paradkar, 2005).
Additionally, using excipients such as sodium bicarbonate, while extruding the physical
blend, affects the stability and compatibility of floating dosage compositions. This can be
explained in terms of buoyancy efficiency. The buoyancy lag time for the device can be
up to 3 min (Fukuda et al., 2006b).
The gastric pH in some patients fluctuates and can reach a pH of up to 7.0, as seen in
fasted achlorhydric subjects (Mathias et al., 2015; Russell et al., 1993). Prescribing a
floating tablet to these patients would result in an increased lag time owing to the release
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of CO2 from the traces of sodium bicarbonate (Fukuda et al., 2006b). Consequently, there
is a risk that the floating device will escape out of the pyloric sphincter. Further, it will be
expelled out of the stomach with chyme during gastric emptying (Hwang, Park, & Park,
1998; Wei, Yu, & Bi, 2001). Other techniques that implement effervescent systems has a
drawback, as the system does not float immediately after swallowing the dosage form,
since the process of gas generation has a delayed lag time of up to 20 min. Therefore,
they could be cleared from the stomach before becoming functionally effective
(Alexander Streubel, Siepmann, & Bodmeier, 2006). Most of these systems are single
unit devices (Hwang et al., 1998). Therefore, they lose their benefits early before they
have a chance to function as a floating system in gastric media due to their all-or-nothing
emptying from the stomach. In order to address the aforementioned issues, a
multiparticulate-unit floating system has been developed (Kawashima, Niwa, Takeuchi,
Hino, & Ito, 1991).
Acetaminophen (APAP) was selected as a model drug in the present study, since it
is not a thermolabile active pharmaceutical ingredient (API) and it has been extensively
used previously in developing various formulations via the HME technique (Qi, Gryczke,
Belton, & Craig, 2008). Furthermore, it has a narrow absorption window and is absorbed
in the upper intestinal segment (Davis, 2005) and it is also prescribed to patients to
alleviate abdominal pain after the postoperative procedure (Hyllested, Jones, Pedersen, &
Kehlet, 2002). All these properties make APAP a suitable candidate for developing
floating systems. Eudragit® RL PO (EUD), is one of the polymers that has been widely
used in HME processing (Saerens et al., 2011; Zheng, Cerea, Sauer, & McGinity, 2004;
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Zhu, Shah, Malick, Infeld, & McGinity, 2006). It is a copolymer that has quaternary
ammonium groups. These groups function as salts, increasing the permeability of
dissolution media and make this hydrophobic carrier highly permeable. This permeability
characteristic makes this polymer a good candidate to comply USP-NF monograph for
the extended release preparations of APAP extended release profile specifications.
In the current study, the HME/P-CO2 approach was used to develop a FDDS based
on low-density devices. This single-step, cost-effective, continuous, and efficient
combination method for manufacturing floating gastric devices overcomes the limitations
of conventional methods. In this process, API and pH-independent polymer are used
along with the injection of an inert P-CO2 gas. This study aimed to investigate the effect
of injected inert CO2 gas on the physico-mechanical properties of the controlled-release
hot-melt extrudates to obtain mini-tablets, using EUD as a release-retarding carrier which
resulted in optimal buoyancy required for a floating device, compared to the devices
prepared by the existing approach.

2.2. Materials
Acetaminophen was purchased from Mallinckrodt (St. Louis, MO, USA) and Eudragit ®
RL PO was kindly gifted by Evonik industries (Piscataway, USA). Sodium bicarbonate
was purchased from Fisher Scientific (Hanover Park, IL, USA). CO 2 gas cylinders (pure
clean) were purchased from Airgas (902 Rockefeller St, Tupelo, MS 38801 USA). All
other materials and reagents used in this study were of analytical grade.
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2.3. Methods
2.3.1. Physical blend preparation and HME/P-CO2 process
EUD was sieved (mesh size #35) and blended with 30% APAP with and without
sodium bicarbonate using a V-shell blender (MaxiBlend TM, GlobePharma, North
Brunswick, NJ, USA). The blends were dried in an oven overnight at 30 °C. The
extrudates obtained were in the form of regular rods when only co-rotating twin-screw
extruder (16 mm Prism Euro Lab, Thermo Fisher Scientific, Stone, UK) was used. When
P-CO2 gas was injected at zone 4 of the extruder, the extrudates obtained were in the
form of porous, foamy rods. With optimal torque (around 80%), all formulations (Table
2-2) were extruded at an optimal processing temperature (Table 2-3). Tailoring the ratio
of API/polymer in the formulations, along with the appropriate extrusion temperature
profile, can be utilized to obtain neat and intact extrudate strands and to be convenient for
further downstream procedures (i.e. mini tablet pelletization). P-CO2 was injected into the
barrel of the extruder by means of a high-pressure regulator throughout an injection
nozzle located in barrel segment 4 (Figure 2-1). CO2 gas was pressured and injected into
the extruder using a high-pressure regulator connected to pliable stainless-steel hose with
an armor case ending up in a four-way connection with a pressure gauge, check valve,
and bleed valve connected to the injection port at zone number 4 of the extruder. P-CO2
gas (120 psi) was metered and regulated using a knob. The obtained extrudates were then
cut into mini-tablets (4 mm diameter) using a pelletizer (Type L-001-9482, Thermo
Fisher, Stone, UK).
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2.3.2. Scanning electron microscopy (SEM)
The surface morphology of the mini tablets was studied by SEM. Samples were
mounted on adhesive carbon pads placed on aluminum stubs. Gold was used to coat the
samples by a Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a highvacuum evaporator. A scanning electron microscope was operated at an accelerating
voltage of 5 kV for imaging (JEOL JSM-5600).

2.3.3. Density measurements and porosity calculation
True density of powdered solid dispersion for all the formulations as well as the
pure polymer with and without P-CO2 has been measured. True density of milled solid
dispersion powder was determined utilizing Micromeritics AccuPyc 1330 Gas
pycnometer S/N-4011 (Norcross, GA). Prior to each run, calibration was performed. The
sample was filled in 10-cm3 sample cup and the weight of the sample was noted. True
density was measured at an equilibration rate of 0.0050 psig/min and the number of
purges was set to 10. Bulk density was calculated by measuring the volume of a 5 g
milled extrudate in a 10 ml graduated cylinder. Porosity was calculated by the following
equation (Joshi, Das, & Mukherjee, 1993):

%𝑷𝒐𝒓𝒐𝒔𝒊𝒕𝒚 = 𝟏 −

𝑩𝒖𝒍𝒌 𝑫𝒆𝒏𝒔𝒊𝒕𝒚
𝑿 𝟏𝟎𝟎
𝑻𝒓𝒖𝒆 𝑫𝒆𝒏𝒔𝒊𝒕𝒚

2.3.4. In-vitro buoyancy efficiency and dissolution studies
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The buoyancy efficiency of mini-tablets in terms of lag time and the floating period
was determined using the dissolution method. Dissolution studies were conducted on
USP apparatus II (Hanson SR8) with 900 mL of medium 0.1N HCl, maintained at 37°C ±
0.5°C with a paddle rotation speed of 50 rpm. Data were collected at 0.25, 0.50, 0.75,
1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, and 6.00 h. All buoyancy tests
were performed by visually checking the state of mini-tablets (buoyant, rotated or sunk)
every 1 h up to 12 h and the end point of 24 hrs (Fukuda et al., 2006b). Lag time and
floating period were determined in seconds and hours, respectively. In-vitro release
studies (n = 3) analysis were performed according to USP using dissolution apparatus II
(Hanson SR8), equipped with UV-Vis probes (Rainbow Dissolution Monitor, pION).

2.4. Results and discussion
2.4.1. Extrudates physical appearance and milling efficiency
Extrudates were found to be intact for all formulations (Figure 2-2) except for the
formulation containing 4% and 10% sodium bicarbonate, wherein deformations and dents
in some portions of extrudates (non-intact extrudates) were observed. This was owing to
thermal effect and the higher percentage of sodium bicarbonate present in the blend,
which resulted in the excess CO2 release. This, in turn, affects the quality of extrudates for
further processing, i.e. mini-tablet pelletization and a variation in the size of the mini
tablets would occur. Milling efficiency was significantly enhanced in case of the
formulations prepared by injecting P-CO2 gas (F2 and F5). Therefore, there is a decrease
in milling time and increase in milling efficiency.
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2.4.2. SEM investigations
The SEM images as noticed in Figure 2-3 (a) of the formulation processed by
conventional extrusion method (i.e. with neither P-CO2 nor incorporating sodium
bicarbonate) clearly showed small open pores of approximately 66 µm in size. Since
APAP is hygroscopic in nature, an evaporation process inside the barrel of extruder
results in the formation of small-opened pores. Usually while processing the formulation
at around 100 °C the water molecule droplets present in APAP will evaporate and
converted into a gaseous state and in this rapid movement, it generates small pores. In
contrast, when the only pure polymer is extruded (i.e. no hygroscopic API), no pores
were observed as noticed in Figure 2-3 (f). In addition, the mini-tablets obtained using a
P-CO2 approach contained many closed pores of approximately 200 µm in size, covered
with a thin layer, as seen in Figure 2-3 (b). These covered pores with thin layer have the
size of around 200 µm, but still these mini-tablets have more retarding release behavior,
because they are less dense. Therefore, they are less immersed and part of them is
exposed to the air on the surface of the media. In case of sodium bicarbonate formulation
Figure 2-3 (c,d), they are all opened small oval pores, and the more retarding release is
because they are less dense and more exposed to the air on the top of the media.
Interestingly, as noticed in Figure 2-3 (e) the pores are larger than 200 µm in size and this
explain the more floating period (168 h) in formulation 5 as described in Table 2-3.

2.4.3. Density and porosity measurement
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Porous extrudates were obtained with the aid of P-CO2, and these had a relatively
lower density and higher porosity, than the formulations prepared using sodium
bicarbonate and the conventional method and the data for porosity measurement are
represented in Table 2-3. It has been concluded that the higher %porosity values are with
the formulations prepared by P-CO2 (F2 and F5) in a reproducible manner among
batches. However, the porosity was not reproducible with the formulations of sodium
bicarbonate (F3 and F4), which appeared to be variable. These data are in a good
agreement with buoyancy efficiency in these formulations. P-CO2 gas generates regular
rounded and well-ordered pores and intact extrudate strands, whereas the extrudates
prepared by incorporating sodium bicarbonate suffuse and liberate some carbon dioxide
molecules, resulting in smaller, random, oval pores in some portions of extrudates and
produce clumsy and non-intact extrudate strands. Thus, thermal decomposition of sodium
bicarbonate inside the barrel results in liberation of CO 2, water molecules, and anhydrous
sodium carbonate in the softened polymer (Fukuda et al., 2006b). This might be a
problematic issue in the term of formulation stability over a period of time.

2.4.4. Buoyancy efficiency and dissolution profile
As shown in Table 2-3, the lag time for the proposed approach (HME/P-CO2) is 0
sec, compared with that of the traditional HME approach (approximately 2 min, P <
0.05). The optimized formulation developed using a HME/P-CO2 approach had a floating
period of around 54 h. Also, it had an efficient floating behavior with an optimal drug
release pattern. Formulations containing sodium bicarbonate (F3 and F4) displayed a
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more extended floating period owing to traces of CO 2 in the manufactured mini-matrices.
These traces are released gradually upon contact with gastric media, forming new pores
that are neither filled nor saturated with gastric media, thereby extending the buoyancy of
the preparations. The density of formulation F5 was low (data not shown) owing to the
absence of API, resulting in a longer floating period than that observed for F3 and F4.
Additionally, F5 did not disintegrate even after 7 days. In contrast, in the case of (F2), the
saturated mini-matrices increased the weight of the mini tablets, until they eventually
sank and disintegrated.
In-vitro release profiles of injected P-CO2 mini-tablets in acidic media have given the
optimal sustained-release profile that meets USP-NF specifications after 3 h i.e. not less
than 85% of APAP should be released. In this study, the in-vitro release profile of
optimized formulation F2 was approximately 86.5%, in 3 h (Figure 2-4). Interestingly, F4
gave the most retarding release behavior and this is because of the new born pores that
formed when contacted to the media upon time through the traces of sodium bicarbonate
that has not liberated the CO2 by thermal effect while extruding the blend. Therefore, less
immersed in the media and most parts of mini tablets are exposed to the air. These data in
a good agreement with extended buoyancy efficiency data in F4. In contrast, in F2, CO2
might be entrapped in the closed pores, and the glassy, transparent thin layer covers the
pores. These covered pores hold, embed and incorporate the API firmly. Therefore, the
gradual release of API takes place upon contact with gastric media after swelling of this
hydrophobic thin layer. Therefore, results demonstrate that this floating device is safe in
regard of burst and faster or immediate release of the drug as throughout this device there

21

are relatively bigger large, rounded pores. Thus, generating relatively larger rounded
pores (super porous) via P-CO2/HME technology. This approach provides a superior
alternative for opening new trends for the manufacturing floating devices with the
extended release profiles.

2.5. Conclusion
In conclusion, the floating device formulated in this study by utilizing
tasteless/odorless P-CO2 gas, in conjunction with HME technology, possesses optimal
buoyancy. Using this combined technology, low-density floating devices can be easily
designed and developed for other APIs/polymers. The combination of injecting P-CO2
gas and continuous HME process overcomes the existing limitations commonly
associated with other conventional techniques for manufacturing floating solid dosage
forms. Moreover, the mini-tablets produced using this novel technology, possess superior
buoyancy efficiency in terms of lag time and floating period. This study provides an
important insight into combining HME/P-CO2 continuous technology for the
development of FDDS, which may be useful for large-scale production of floating
devices. However, future studies on other gastric APIs are required for additional
applications.
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Table 2-1: Limitations of former approaches
Approach

Limitation(s)
•

Patients on salt restriction diets or have
congestive heart failure, kidney function
impairment, and high blood pressure are
on

risk by chronic

use

of these

formulations because of high sodium
content.

FDDS

prepared

by

hot-melt

•

Sodium bicarbonate by thermal effect

extrusion process with the aid of

while extruding in conventional extrusion

sodium bicarbonate

process

converts

to

CO2,

sodium

carbonate and water. Therefore, sodium
carbonate and water might have an
impact on drug stability or drug-excipient
incompatibility over period of time.

•

Acid reflux and irritation of esophagus
through esophagus sphincter can be
caused by these gas-generating systems.

•
23

Sodium

bicarbonate can

act

as

an

alkalizer and
microenviromental

increase

the

pH

by

microenvironmental pH modulation that
FDDS that utilize effervescent

causes some limitations in terms of

system

dissolution aspects especially the APIs
that dissolve in acidic media.
•

Gastric rupture caused by excess gas
release (when combined with gastric
acid).

•

Stability and lipid polymorphism issues.

•

Residual organic solvent in the final

FDDS that utilize low density lipid

Microsphere and gel rafting system

product.
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Table 2-2: Formulation compositions
Components

F1

F2a

F3

F4

F5a

F6

APAP

30

30

30

30

N/A

N/A

70

70

70

70

100

100

N/A

N/A

4

10

N/A

N/A

%(w/w)

Eudragit® RL
PO
%(w/w)

Sodium
bicarbonate
%(w/w)

aFormulation

prepared by injecting P-CO2 gas in Zone 4.
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Table 2-3: Process parameters and floating properties
Process-Related Measurements

Floating Properties-Related Measurements
Drug
relea

For
Screw

Temperatur

speed

e

(rpm)

°C

mu

Torque

lati

Floating

se

periods

perce

(h)

ntage

Lag time
% Porosity

%

(Sec)

on
after
1h

Rotated and
F1

100

90

70-81

53.66

N/A

80.2

sank

F2b

100

110

83-86

63.85

0

54

57.2

F3

100

110

69-78

54.00

120

72

72.1

F4

100

110

67-79

55.13

32

144

42.5

F5b

100

165

82-86

66.50

0

168

N/A
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F6

100

bFormulation

150

74-79

53.62

prepared by injecting P-CO2 gas in Zone 4.
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Sank

N/A

N/A

Figure 2-1: (a) Schematic representation of preparation of floating mini-tablets using 16mm hot-melt extruder in conjunction with P-CO2 injection, (b) Standard screw
configuration
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Figure 2-2: Digital picture of the extrudate strands
(a) F1: prepared using conventional HME process (control formulation), (b) F2:
prepared using HME process with P-CO2 injection, (c) F3: prepared using
conventional HME process with sodium bicarbonate (4%), (d) F4: prepared suing
conventional HME process with sodium bicarbonate (10%), (e) F5: HME process for
pure polymer (EUD) with P-CO2 injection and no sodium bicarbonate, (f) F6:
conventional HME process for pure polymer (EUD) with no P-CO2 injection or
sodium bicarbonate
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Figure 2-3: SEM images of mini tablets
F1: prepared using conventional HME process (control formulation), F2: prepared using
HME process with P-CO2 injection, F3: prepared using conventional HME process with
sodium bicarbonate (4%), F4: prepared using conventional HME process with sodium
30

bicarbonate (10%), F5: HME process for pure polymer (EUD) with P-CO2 injection and
no sodium bicarbonate, F6: conventional HME process for pure polymer (EUD) with no
P-CO2 injection or sodium bicarbonate

Figure 2-4: Drug release % in 0.1 N HCl
F1: prepared using conventional HME process (control formulation), F2: prepared using
HME process with P-CO2 injection, F3: prepared using conventional HME process with
sodium bicarbonate (4%), F4: prepared suing conventional HME process with sodium
bicarbonate (10%)
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CHAPTER 3:
DEVELOPMENT AND CHARACTERIZATION OF SUSTAINED-RELEASED
DONEPEZIL HYDROCHLORIDE WITH VARIOUS HYDROPHOBIC CARRIERS
UTILIZING HOT MELT EXTRUSION TECHNOLOGY
ABSTRACT
Manipulating the release profile for such a hydrophilic drug such as Donepezil
Hydrochloride (DH) could be challenging. The precise and reproducible behavior of the
release profile is often crucial to obtain the desired therapeutic outcomes. The aim of this
work was to obtain release profile of hydrophilic drug from hot-melt extruded solid
dispersion via rational screening of hydrophobic carriers that have features of pH
independent swellable and low-permeable as in Eudragit® RS PO (E-RS) and pH
independent non-swellable as in ethyl cellulose N7 (EC-N7), and lipidic compositions as
in Compritol® 888 ATO (C-888) with or without pore-forming agent. DH, E-RS, EC-N7
and C-888 was selected as the model drug and carrier excipients, respectively. Mannitol
(MNT) was chosen as the temporary pore-forming agent. The thermal analysis showed
that both drug and C-888 preserved their crystallinity within solid dispersion. Upon
dissolution test, mannitol could generate pores and the drug release rate was
proportionally correlated to the mannitol content. Tailoring the ratio of C-888 and MNT
in the formulations, along with an appropriate extrusion temperature profile, resulted in
modifying the release of DH and obtained the preferable release pattern. The burst release
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issue relevant to other hydrophobic carriers could be problematic for patients where it
might cause dose dumbing leading to initial sharp spike of DH levels in blood as in
immediate release formulations. Therefore, C-888 has been chosen for further
investigations to obtain tablets with high integrity. Optimized tablets were compared to
the marketed formulation Aricept ® in terms of release studies. Therein, the optimized
formulation provided monophasic behavior of extended release profile close the release
behavior of Aricept® with good tablets characteristics. It has been concluded that hot melt
extrusion (HME) technique can be utilized for the manufacture of DH sustained release
tablets with improve tablet integrity and characteristics by co processing of tablet
excipient with DH/C-888. Tailoring the ratio of C888, tablet excipient and MNT in the
formulations, along with an appropriate extrusion temperature profile, resulted in
modifying the release of DH and obtained the preferable release pattern.

3.1. Introduction
Donepezil Hydrochloride (DH) (melting point: 220-222°C) is a reversible inhibitor of
acetylcholinesterase and has its effect by increasing the concentrations of acetylcholine
and by enhancing cholinergic function in the brain. It is indicated for the treatment of
mild to moderate dementia associated with Alzheimer’s (Rogers, Farlow, Doody, Mohs,
& Friedhoff, 1998). DH’s aqueous solubility is ≥20 mg/mL. Therefore, it’s considered
highly water soluble active pharmaceutical ingredient (API). Hydrophobic materials such
as ethyl cellulose is used in pharmaceutical formulations as a carrier to extend the release
of APIs over a prolonged period of time (Almeida et al., 2012). Ethyl cellulose (EC-N7)

33

is a cellulose ethyl ether, non-swellable, insoluble component. Another example is
Eudragit® RS PO (E-RS) which is powdered cationic low permeable hydrophobic
polymer. Lipid matrices such as Compritol® 888 ATO (glyceryl behenate USP-NF) (C888), usually used as a pH-independent sustained-release carrier and has a melting point
of around 74 oC, (Hydrophile-Lipophile Balance (HLB) = 2). It has been extensively used
previously to extend the release of water-soluble APIs. It might be highly effective even
for highly water-soluble API due to its lipophilic nature and reduced wettability ( a
Obaidat, 2001; Vithani et al., 2013a). C-888 is a hydrophobic carrier that incorporates
API molecules in the tablet matrix and has specific uses in tablet compression, provides
pH-independent drug release, has high resistance to physiological conditions due to its
non-digestible nature, and has history of use in internationally approved and
commercialized drug products ( a Obaidat, 2001). In this study, HME as a processing
technology has been utilized to produce the sustained release formulations of DH.

HME is a common technology that can be applied to many pharmaceutical
preparations especially to solid dispersions. Either raw materials alone or blends can be
mixed and extruded under certain conditions as a feasible and continuous process. There
are some parameters of HME that should be considered such as feeding rate, shearing
force, temperature, die geometry, barrel design, screw rotating speed. With optimization
these parameters, formulators can contribute in production of a desired final product with
preferable drug release profile, uniformity of size, shape and content. HME offers some
advantages over other conventional methods. For example, it is a one-step solvent-free
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process, giving a continuous operation, scalable process which has fewer processing
steps, requires no compression and can improve bioavailability due to dispersion of the
drug at the molecular level in such a dosage form (Crowley et al., 2007; Michael a Repka
et al., 2012; Shah, Maddineni, Lu, & Repka, 2013b). The growing demand for versatile
continuous processes in pharmaceutical industry has made HME a preferable technique
in their production lines. The reduction of waste, energy, and ﬁnally costs are advantages
of continuous process as compared to a single batch process such as heat fusion process
(melt and mix methods) (Li et al., 2006; Plumb, 2005; Yvonne Rosiaux, Jannin, Hughes,
& Marchaud, 2014). Some of conventional methods like sintering techniques have been
investigated (R. Singh, Poddar, & Chivate, 2007). Therefore, these techniques could
mimic the residence time when we decrease the screw speed of extruder. HME is a
continuous process version of batch process of sintering techniques. Few limitations that
restrict the use of HME in the pharmaceutical industry are that it requires a higher energy
input compared to other techniques and may exclude some thermo-labile compounds due
to high processing temperatures. However, in the case of lipid matrices such as C-888,
there is no need for this high-energy input since most of them have relatively lower
melting point as compared to other hydrophobic carriers such as EC-N7 and E-RS. It is
widely accepted that HME technology is an innovative and feasible approach in the
preparation of various pharmaceutical drug delivery systems such as mini tablets,
granules, immediate and modified release tablets, oral fast dissolving systems, and
transdermal delivery systems. HME technology can also be used for taste masking of
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bitter active substances by way of incorporating them in hydrophobic matrices (Crowley
et al., 2007; Michael a Repka et al., 2012; Shah et al., 2013b).

Formulations factors that are based on different ratio of API/hydrophobic carriers and
mixture of two hydrophobic carriers with the API with or without pore former e.g.
mannitol (MNT) can play a critical role on the final product characteristics. It can be used
to produce different extended release profiles (i.e. stable monophasic or diphasic release
profile) as well as to produce different physicochemical characteristics for highly soluble
drugs like DH. Controlling either formulation parameters (e.g. ratio of DH/carrier, and
formulation composition) or processing parameters (e.g. processing temperature, screw
speed) could play a significant role on the behavior of the drug release profile as well as
physicochemical properties of the DH within the matrix. The effect of the processing
temperatures, formulation composition, the impact of the fillers on drug content, tablet
disintegration, DH/carrier ratio and compression force have not been investigated yet. In
a previous study, the influence of some of these parameters on a different API (diclofenac
sodium) release behavior has been studied (Vithani et al., 2014, 2013a).

Lipid aging could lead to instability during storage. It is the main disadvantage when
using lipids in pharmaceutical formulations as their physical properties could change
during storage. One of these effects for example is an increase of melting ranges, melting
enthalpy, pore formation on the surface, rheological changes, and a decrease in tensile
strength (Reitz & Kleinebudde, 2007).
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In this study, HME has been utilized to prepare solid dispersions of DH in C-888
matrix and in other hydrophobic matrices, which are EC-N7 and E-RS in order to
produce a more desirable release profile. In the case of lipid matrix of C-888, we have
compared the results obtained from this process via HME with the results of conventional
process such as “hot fusion method” (Li et al., 2006) in order to observe how efficient
HME on manufacturing a desired final product. The main objectives of this study were to
develop and evaluate sustained-release DH formulations using hydrophobic carriers such
as C-888, EC-N7 and E-RS utilizing HME technology and thereby avoid the side effects
(nightmare, insomnia, anxiety, nausea, emesis and/or diarrhea) associated with initial
sharp spike in blood DH levels for immediate release formulations. Formulations that
provide immediate release of DH are administered once a day. However, the peak plasma
concentrations are reached in 2 to 5 hours, resulting in initial sharp spike in blood plasma
levels (Fanda, Singh, & Vivek, 2011). This sharp spike could cause undesirable
cholinergic side effects as mentioned above (Rogers et al., 1998), (Fanda et al., 2011).
Furthermore, the specific aims of this study were to study the effect of the extrusion
temperature on the drug physical state and drug release profiles from lipid carrier and
compare it to conventional-processed formulation. In addition, improvising drug content
and content uniformity for lipid-based tablets prepared via HME. The extrusion of premixed tablet excipients (i.e. microcrystalline cellulose (MCC), and MNT) is considered
as a critical aspect in this study. Co processing tablet excipients is expected to be cost
effective process since there are fewer manufacturing steps. For instance, tablet’s
excipients blending step. However, it is mandatory to investigate the effect of the added
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excipients on tablet’s physico mechanical properties (e.g. drug content and tablet content
uniformity, hardness, friability, dissolution profile). To the best of our knowledge, there
is no published work has been done on DH via HME.

3.2. Materials
DH USP was purchased from Wuhan Hengheda Pharm Co. (Wuhan, China). C-888
was kindly received by Gattefossé (Saint-Priest, France). EC-N7 was obtained from
Ashland (Ashland Aqualon Functional Ingredients, Wilmington, DE, USA). E-RS were
kindly gifted by Evonik (Piscataway, USA) and Avicel® PH 102 (MCC) has been
received from FMC Biopolymers (1735 Market Street, Philadelphia, PA 19103).
Magnesium stearate were purchased from Spectrum Chemicals (Gardena, CA). Pearlitol ®
(MNT) was received as a gift sample from Roquette America Inc. (Keokuk, IA, USA).
Stearic acid was purchased from Mallinckrodt Chemical Ltd. (Bedminster Township, NJ,
USA). Marketed Aricept® tablets were purchased from local university pharmacy
(Oxford, MS, USA). All chemicals and solvents utilized for analysis in the study were of
analytical grade and were obtained either from Spectrum Chemicals or Thermo Fisher
Scientific.

3.3. Methods
3.3.1. Thermogravimetric analysis (TGA) and differential scanning calorimetry
(DSC)
The thermal stability of DH and the carriers at the employed processing temperatures
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was determined by Thermogravimetric analysis (TGA, Pyris 1 TGA Perkin Elmer). A
Perkin Elmer Pyris 1 TGA running Pyris manager software (PerkinElmer Life and
Analytical Sciences, 719 Bridgeport Ave., Connecticut, USA) was utilized to do
thermogravimetric analysis of samples. Drug and its excipients were evaluated for
thermal stability at high temperatures. Three to four milligrams of the sample were
weighed and heated from 25°C to 250°C at 10°C/min heating rate under an atmosphere
of nitrogen (data not shown). Differential scanning calorimetry (DSC, Diamond DSC,
Perkin Elmer) was utilized to determine the physical state of different API/carrier ratios
in each physical mixture and extrudate (EXT). The physical state of pure drug, pure
carrier, physical mixtures and EXTs was studied. The heating range used was from 30 0C
to 250 0C at a heating rate of 20 0C /min under nitrogen (N2) atmosphere. Due to the low
melting point of lipid, it was heated from 30 0C to 100 0C at the same scanning rate.
Sample prepared weighing with an approximate initial weight of 4–5 mg in a sealed
aluminum pan. Certain software has been utilized to calculate the endothermic onset and
peak temperatures at melting. The name of software is Pyris manager software (Shelton,
CT, USA). It was used to analyze the data generated to evaluate crystallinity. The DSC
was calibrated initially with an Indium reference. In addition, the drug/lipid miscibility
was estimated using Hoftyzer and Krevelen approaches and the Hansen solubility
parameters (Hansen, 1969).

3.3.2. Solubility parameter calculation for optimized formulation
Solubility/miscibility is an important parameter in solid dispersion formulations.
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Hansen solubility parameters can be obtained from the literature. However, it can be
calculated through Molecular Modeling Pro, v6.2.8 (ChemSW, Fairfield, CA, USA). This
software can be used conveniently to calculate the solubility parameters for certain
pharmaceutical materials via implementing their corresponding melting points and
molecular structures.

3.3.3. HME processing method
For screening purposes, three different carriers, C-888, EC-N7 and E-RS have been
used (alone or in combination) at different ratio and processing parameters (Table 3-1, 32, 3-3) to evaluate their effect on sustaining the DH release. Materials were blended using
a V-shell blender (GlobePharma, Maxiblend®) with and without mannitol as a pore
former and samples analyzed for drug content and content uniformity. Prior to HME,
materials were sieved using USP mesh size #35 to remove any aggregated and
agglomerated particles. The blended materials were extruded on a 16 mm Prism Eurolab,
ThermoFisher Scientific Co, rotating twin-screw extruder utilizing a round-shaped die to
produce rods EXT. In addition, to study the effect of processing temperature on lipid, the
materials ran through the heated barrel with screws rotating speed of at 50 rpm and
the temperature for all zones of the extruder was set at 70 or 75 or 77 °C except for the
last zones and the die which were set at 70 °C to make EXTs cooled down and solidified
(Table 3-4). The reason why different temperatures have been set is to see the effect of
temperature degree on drug and lipid crystallinity and the drug release profile. The
processing temperature profile and screw speed were based upon the physical properties

40

of hydrophobic carriers in the preliminary studies. Resulting EXTs were further
processed using a comminuting mill (Fitzpatrick, Model “L1A”) and then sieved using
USP mesh size #35.
Another part of this study is to improve the drug content and content uniformity of
the optimized formulation from screening stage based on drug release profile which is
(DH:Lipid). As shown in (Table 3-5, 3-6), DH (33.3 - 50% w/w) (1:2, 1:1 ratio) and C888 were blended and extruded as the same procedure and processing conditions as
previously mentioned during the screening stage but with and without premixed MCC as
a tablet diluent while extruding the blend to observe the effect of pre-mixed MCC on
drug content and content uniformity as well as release profile.

3.3.4. Conventional heat fusion processing method
It’s also called melt and mix. This method only used for C-888 to compare its
performance with the formulation from HME. In this processing method, C-888 has been
melted in porcelain casseroles at 100 °C until a homogeneous melt was obtained, then
DH has been added and mixed manually to the homogenous melt. The mixture was kept
to gradually cool down with continuous stirring until the congealed mass was obtained.
Then the mass melt was milled using the same milling method as mentioned before in
HME processed formulations. Subsequently, the mass was ground, pulverized and passed
through a then sieved using USP mesh size #35. All processed powders were stored in a
desiccator at room temperature until further use is needed.
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3.3.5. Physico mechanical evaluation for milled EXTs properties for optimized lipid
formulation
Bulk and tapped density was calculated by measuring the volume of a 5 g milled EXTs
in a 10 mL graduated cylinder(B. K. Almutairy et al., 2016). Firstly, the initial occupied
bulk volume in the cylinder was noted. Secondly, after tapping the cylinder 100 times,
the tap volume was noted. The bulk density (𝜌 𝑏𝑢𝑙𝑘) and tap density (𝜌 𝑡𝑎𝑝) were
calculated by dividing the weight of milled EXTs over the respective volume. Using
following equation (Eq. 1), the Carr’s compressibility index (CI) was calculated:
𝐶𝐼 = (

𝜌 𝑡𝑎𝑝−𝜌 𝑏𝑢𝑙𝑘
𝜌 𝑡𝑎𝑝

) 𝑥 100 ---- Eq. 1

Hausner ratio (HR) was obtained by dividing (𝜌 𝑡𝑎𝑝) over (𝜌 𝑏𝑢𝑙𝑘).

3.3.6. Tablet processing
The milled EXTs were mixed with tableting excipients (MCC and magnesium stearate)
(Table 3-5, 3-6) and compressed into tablet equivalent to 23 mg of DH with compaction
force of 600 and 1500 psi. Tablets were compressed on a manual tablet press using 10
mm round concave punch to a final tablet weight of 300 mg. The tablets, having
luminous surfaces, were stored in a plastic bottle until further use. Tablets were evaluated
for thickness, hardness, friability, and in-vitro release profiles. In addition, drug content
and tablet content uniformity tests have been conducted. DH content has been analyzed
using a Waters HPLC-UV system (n=3) (Waters Corp, Milford, MA). For improving
drug content, the pre-mixed MCC formulations were compressed on single punch tablet
press (MCTMI, Globe pharma), using 8 mm round flat punch with compaction force of
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1500 psi. Magnesium stearate (1%) was added as a lubricant just before the direct
compression process, and each compressed tablet weighed 200 mg to mimic the weight
of Aricept® which is the commercial product of DH that has been used in this study as a
control formulation.

3.3.7. Tablet characterization
Some standard characterization tests were achieved on tablets manufactured from
extruded materials. The thickness and diameter of the tablets was measured using a
micrometer. Disintegration testing was performed via disintegration apparatus. Friability
testing was performed in a friabilator (Roche friabilator). To test the hardness of tablets,
A VarianVK200 (Agilent technologies, 13000 Weston Pkwy, Cary, NC, 27522) hardness
tester was used. Tablet content uniformity test was achieved by drug assay via HPLC
method. Tablet weight uniformity test was performed via measuring each tablet after
direct compression via Mettler Toledo scale. Six replicates were tested (n=6).

3.3.8. In-vitro release studies
In-vitro release studies for either milled EXTs or tablet equivalent to 23 mg DH were
performed using a USP Type-II dissolution apparatus with 900 mL of pH 6.8 phosphate
buffer at 37±0.5 0C at 50 rpm for 10 hours (Azarmi, Roa, & Löbenberg, 2007;
“Dissolution Methods,” 2014). All dissolution samples were analyzed using a Waters
HPLC-UV system (n=3) (Waters Corp, Milford, MA). Paddle speed was set at 50 rpm.
Samples were collected at every 0.5, 1, 2, 3, 5, 8 and 10 h, filtered and then analyzed
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using an HPLC. We compensate the withdrawn amount for sample with an equal amount
of fresh dissolution media by adding back to the dissolution vessel at each time point. We
plot the release profile for percent release to time. Model independent similarity factor 𝑓 2
has been used to compare among dissolution profiles. Furthermore, statistical analysis
was conducted using ANOVA to compare the profiles. Based on FDA guidelines, it’s
well known that if the calculated 𝑓 2 is between 50-100, then the profiles are considered
to be similar (“Guidance for Industry. Dissolution testing of immediate release solid oral
dosage forms,” 1997).

3.3.9. HPLC method
An in-house reverse-phase HPLC-based analytical method was developed for the
determination and quantification of DH. This method was validated according to a
previous research group (Pappa, Farrú, Vilanova, Palacios, & Pizzorno, 2002). The
HPLC equipped with a UV detector, Waters Symmetry shield 5μ C18 column (250 x 4.6
mm) and an isocratic mode of elution. The mobile phase was a mixture of methanol, 0.02
M buffer phosphate and trimethylamine (50:50:0.5). Buffer phosphate was prepared by
dissolving 2.4 g of monobasic sodium phosphate in 900 ml of water, mixing with 10 ml
of trimethylamine and adjusting to pH 2.7 ± 0.5 with phosphoric acid. The mobile phase
was filtered through a nylon membrane (pore size 0.45 µm) and degassed before use.
Chromatography was performed at room temperature using a 1.0 ml/min flow rate and a
15 min run time. In these conditions, DH retention time (t R) was roughly 9 min. The
injection volume was 20 µL and ultraviolet detection was at a wavelength (λmax) of 268
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nm (2 aufs). The column temperature was 40 °C.

Finally, the acquired data were

processed using Empower 2 build 2154 software (Waters Inc., Mount Holly, NJ, USA).

3.3.10. Scanning electron microscopy (SEM)
Surface morphology of the pure drug and milled EXTs was studied by SEM. Samples
were mounted on adhesive carbon pads placed on aluminum stubs. Gold was used to coat
the samples by a Hummer ® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a
high vacuum evaporator. A scanning electron microscope operating at an accelerating
voltage of 0.8 kV was used for imaging (JEOL JSM-5600). The morphology of
formulations might reflect the crystallinity status of the DH.

3.3.11. Statistical analysis
The data were expressed as the mean ± standard deviation (SD). The confidence
interval was chosen to be 95% and a statistically significant difference was determined at
a minimal level of significance of 0.05 using Student’s t-test.

3.4. Results and discussion
3.4.1. TGA
Prior to HME, we could determine the maximum processing temperatures by utilizing
TGA. This analysis indicates thermal stability for APIs and excipients/carriers being
processed via HME by determining the amount of weight loss due to decomposition as a
function of temperature. In present study, it has been found that less than 2% degradation
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below 250 0C for the neat martials, physical mixtures and EXTs at various drug: carriers’
ratio and different temperatures profiles (data not shown). TGA confirmed the thermal
stability of API and excipients/carriers at extrusion temperature utilized during
processing as well as provide a working temperature range. Therefore, as a crucial aspect,
it has been concluded in our study that the processing temperatures studied were
convenient to employ during the extrusion process.

3.4.2. DSC
The solid dispersion EXTs were characterized via a thermal and diffraction techniques
such as differential scanning calorimetry (DSC) to determine the API state within
hydrophobic matrix.

Physical state of DH was found to be either crystalline or

amorphous depending on carrier used and processing conditions. In this study, DSC was
utilized to characterize the physicochemical properties as physical mixture (PM), solid
dispersions

(EXT)

and

as

individual

neat

components.

Since

change

in

crystallinity/amorphousity or change from one polymorph to another often exhibit
significant differences in solubility, bioavailability, processability and physical/chemical
stability, these thermal studies have been achieved to evaluate the effect of processing on
the crystallinity of the DH and lipid. As we can see in DSC graph (Figure 3-1,3-2,3-3,34), neat DH has two characteristic melting endothermic peaks at around 145 0C and 228
0C

(Subedi, Ryoo, Moon, Chun, & Choi, 2012). In addition, lipid has a characteristic

melting endothermic peak at around 74 0C. For all EXTs, the first melting endothermic
peak completely disappeared. The EXTs containing E-RS as a hydrophobic carrier or
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MNT as a pore former did not exhibit melting endotherms, indicating that DH rendered
amorphous during the extrusion process which is not preferable in our study since the DH
is already highly soluble drug. The melting endotherm for lipid was apparent in all EXTs
but less intense (i.e. less delta H “enthalpy”) compared to the pure lipid and physical
mixture indicating that the extent of crystallinity of the lipid was greatly reduced. This
means that extrusion process has an effect on lipid crystallinity and this is beyond the
scope of this study. Lipid endothermic melting peaks were slightly shifted to around 70
0C

for all drug loadings indicating negligible drug–lipid interactions. Regarding the

formulation that has mixture of EC-N7 and lipid (1:1) containing DH, it was indicated
that the lipid was dispersed within the EC-N7. The reduced melting endotherm of lipid in
EC-N7:lipid formulation impart that a fraction of the lipid material recrystallizes as a
separate phase before EC-N7 vitrified (solidified)(J. M. Keen et al., 2015). This
crystalline phase of lipid was observed in DSC graphs. These findings mean that in some
formulations DH has partial crystallization within the carrier matrix and has not
converted completely to higher energy amorphous form. This amorphous is not
preferable in our study because of the risk of related stability issues if there is any. Such
an issue that consequently affecting the relevant dissolution profile and other
physicochemical aspect.

3.4.3. Solubility parameter calculation for optimized formulation
A three-dimensional Hansen solubility parameter impart information about physical
state and interactions such as dispersive, polar, and hydrogen bonding interactions of a
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molecule, and it could be used to characterize the interactions between formulation’s
compositions(Hancock, York, & Rowe, 1997). It is a very useful tool in pharmaceutical
applications. It could predict the API morphology, drug–carrier miscibility in the solid
dispersions, and the drug–excipient interactions in the field of pharmaceutical
development. The effective solubility parameter obtained from Hansen method for DH
and lipid were 28.3 and 19.6 MPa1/2, respectively. Theoretically, in order to observe at
least partial miscibility between the drug and the carrier, the solubility parameter
difference () between them is required to be less than 7.0 MPa1/2 (Forster, Hempenstall,
Tucker, & Rades, 2001; Greenhalgh, Williams, Timmins, & York, 1999). In the present
study, ()

is 8.7, which is significantly more than 7.0 MPa1/2, indicating of

immiscibility of DH in Lipid.

3.4.4. HME processing method and carriers screening studies
The formulation with lipid was extrudable at the lowest processing temperatures (6874 °C) (Table 3-1), whereas in the case of E-RS, it was processed at a relatively higher
temperature (150 °C) as described in Table 3-3. A combination of DH with a mixture of
lipid and EC-N7 (1:1:1) has a significant effect to process the blend with relatively lower
processing temperature (100 oC) compared to DH with EC-N7 (140 oC) as described in
Table 3-2. Stearic acid has been utilized as processing aid. The formulation was
compressed and densified in metering section and die.
In our preliminary study, we processed some batches by feeding manually, we
noticed that when we stop feeding there is more residence time and less pushing
48

force caused by solid lipid material. This cause lipid to be melted and decrease the
output product and increase the processing time. To identify a suitable carrier matrix
to produce an ideal stable release profile that conforms with USP specifications and
mimic the marketed formulation (Aricept ®), different carriers such as EC-N7 and ERS and C-888 were evaluated for extrudability and desired release profiles.
Optimized HME processing conditions for carriers’ screening is shown in Table
3-1, 3-2, 3-3. According to release profile in terms of stable monophasic sustained
release profile, we found out that lipid is the most appropriate drug release profiles. It
gave us nearly ideal zero order release profile. It doesn’t have burst release as other
carriers. When using EC-N7 and E-RS as a matrix forming, during dissolution within
first hours, DH release behave a faster release and this not preferable and could give
a spike plasma drug level. Lipid was picked for further investigations since it doesn’t
give initial burst release and retain crystallinity of DH. In addition, in HME process,
there is DH transformation into partial or total metastable amorphous form of DH as
in case of E-RS. It might recrystallize during storage and as a consequence, it would
affect the dissolution profile afterward which is our goal in this study to keep a stable
sustained release profile. To make sure that we preserve the drug crystallinity, we
prefer to process at the lowest processing condition. Lipid can be used as a
processing aid (J. Keen, Hughey, Bennett, Jannin, & W. McGinity, 2011) and it’s
alternative to chemical plasticizer. Lipid did not undergo to any chemical
degradation such as acid hydrolysis when extruding at higher temperature (Y
Rosiaux, Girard, Desvignes, Miolane, & Marchaud, 2014b). In case of extruding the
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lipid at higher screw speed, because of friction of screw to the lipid material
generates extra source of heat, lipid starts to be liquefied so that we chose 50 rpm
screw speed as the optimized speed instead 100 rpm. Lower than 50 rpm speed
causes more residence time and the lipid gets liquefied as well and there a risk
degradation of API because of longer residence time is attained. In case of lipid,
when we extrude above the melting point, the resulting material is in liquid form.
However, when extruding at away less than melting point of the lipid, it would give a
granular/powdery solid rod EXTs. Extruding with EC-N7 and E-RS at the set
temperature gave opaque solid rod EXTs. C-888, owing to its thermostable nature,
have been utilized to form HME matrices. C-888 melts around 74°C and have been
extruded below its melting point at around 70 °C (Michalk, Kanikanti, Hamann, &
Kleinebudde, 2008; Y Rosiaux, Girard, Desvignes, Miolane, & Marchaud, 2014a;
Vithani et al., 2013b; Windbergs, Strachan, & Kleinebudde, 2009). There are several
advantages of using them as a processing aid instead of chemical plasticizers along
with other hydrophobic polymers. One of these advantages is lower processing
torque can be attained compared to EC-N7 and E-RS alone due to lower melting
point of C-888. When used C-888 as a processing aid, the processing temperature
significantly decrease to (100 °C) for EC-N7 polymer. Barrel temperature and screw
speeds of hot melt extruder were optimized for maximum yield and were set
according to observations made from thermal studies and final EXT. Therefore, all
three-hydrophobic forming matrix with DH showed excellent extrudability under the
utilized processing parameters. Blends of the lipid and hydrophobic polymers can be
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extruded and result in improved physico-mechanical properties; however, the process
needs further optimization in terms of dissolution profiles, which is the subject of
future studies.

3.4.5. Tablet’s excipient MCC co-processed with lipid to improve tablet integrity
Co extrusion of premixed tablet excipients is a critical aspect in pharmaceutical
industry and it has not been completely addressed yet. One of the major challenges while
extruding lipids is that they have poor followability within the extruder barrel. This
caused a drug content and content uniformity variation in this project. For optimized lipid
formulation beside EC-N7 and E-RS. C-888-DH-MCC interaction, DH crystallinity,
dissolution behavior, tablet integrity, lipid aging /API stability studies are critical aspects
in this project which is a theme of a future study. Lipid can be extruded with tablet
excipients such as dibasic calcium phosphate anhydrous (DCPA) (Vithani et al., 2014,
2013b). To the best of our knowledge, MCC is the first time to extrude as a tablet’s
excipient. Tablet’s excipients co processing is assumed to reduce processing steps (i.e.
blending of tablet excipients), labor work and manufacturing time. Therefore, premixed
tablet robustness in terms of drug content, tablet content uniformity, hardness, friability,
and dissolution profile were investigated in our study. Tablet compositions are shown in
Table 3-5, 3-6. The extruding temperatures zones for the premixed MCC formulations
was optimized and set to get the continuous and neat rod EXTs (Figure 3-5) at
temperatures above C-888 melting point for the optimized formulations for further
investigations. MCC was added to lipid matrix because of poor cohesive forces between
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lipid particles since lipid is extremely hydrophobic in nature (Vithani et al., 2014).
Therefore, co processing premixed MCC approach has been utilized to improve tablet
integrity. Torque for the premixed MCC formulations compared to DH with lipid alone
was higher. The reason is because more solid-state particles of DH and MCC. MCC has
high melting point at around 270 ºC then it increased the resistance of the barrel because
of frication forces leading to higher torque. For the optimized formulation after screening
stage, when processing MCC for conventional tablet preparations, solid bridges by
mechanical force via direct compression can occur. The MCC is not completely impeded
within matrix tablet. However, interconnection bond after melting lipid (DiNunzio,
Martin, & Zhang, 2010; Nyström, Alderborn, Duberg, & Karehill, 1993; F. Zhang, 2016)
and intragranular and intergranular bonds with lipid while extruding the blends might
occur (Y.-E. Zhang & Schwartz, 2003). Therefore, it can be concluded that this fusion
bonding of MCC with lipid while extruding, made MCC completely embedded within the
matrix and prevent tablet splitting and burst release in dissolution media instead of
complete disintegration which was after 2 hrs in our case when MCC is not co processed
via HME with the rest of formulation components. For the formulation 300 mg tablet of
DH with lipid, the separation of tablet into parts was the main issue after contact with
dissolution media after 15 minutes (i.e. cracking, capping) leading to faster release and
complete release within 5 hrs. Therefore, we propose to co-extrude tablet excipient MCC
to observe the effect on tablet integrity. The measured hardness with co extruded material
was independent to the compaction force although the co extruded formulation is mixed
with filler (i.e. MCC). However, with conventional methods of adding tablet excipient,
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hardness was dependent on the compaction force. This can be explained as the MCC
being embedded deeply within the matrix in case of premixed formulations whereas in
the conventional formulation, MCC particles surround the solid dispersion particles of
DH and lipid. The friability was less 1% that indicating lipid matrix tablet robustness.
The EXT granules showed good CI which was between 15% to 16%. The less carr’s
compressibility index is because of hydrophobic nature of lipids. After co extrusion with
these kinds of fillers, there is no capping no lamination when contact to dissolution
media. In addition, no lipid melting, egress, spread during tablet compression which is
what we faced with conventional tablet processing in case of high ratio of lipid. These
findings are in agreement with a previous study (Y.-E. Zhang & Schwartz, 2000). The
formulations with C-888 along with MCC were extrudable at the lowest processing
temperatures (70-75°C) but the strands were defected (Figure 3-5 b). However, they were
harder and neater at higher temperature 77 °C (Figure 3-5 c) compared to DH: lipid
(Figure 3-5 a) which were difficult to handle. These harder strands will be beneficial in
downstream processing. The tablet formulation consisting of formulation DH: Lipid:
Mannitol (1:2:0.075) milled EXTs demonstrated an average tablet hardness of 10 kp and
thickness of 4.24 mm. The tablets were less than 0.1% friable but faster release and
capping issue in dissolution media. Therefore, we utilize the co extrusion of tablet
excipients. The premixed formulation milled EXTs tablets demonstrated an average
tablet hardness of 6.8 kp and thickness of 3.2 mm. In addition, the friability was less than
1%. The reason why the hardness is decreased is because as a result of decreasing the
tablet weight (i.e. to 200 mg to mimic the marketed formulation), the amount of MCC
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would be decreased. MCC has been reported to increase tablet strength in a certain
amount and ratio. Hausner ratio is for the premixed formulation was 1.13 which indicate
good flow properties.

3.4.6. Heat fusion processing method
The objectives of this study are to investigate the influence of traditional heat fusion
processing techniques on lipid-based formulations and compare them to those prepared
by HME processing techniques. The fusion method produces granules from congealed
mass. This congealed mass has been reported to decrease the drug release behavior
compared with traditional direct compression and wet granulation method. The efficient
and intense mixing while extruding the material inside the barrel can incorporate more
API particles within the lipid matrix and make the formulation with a more slower release
behavior compared to heat fusion (data not shown). The reason might be because the
pore architecture is different in case of formulation prepared by continuous HME. It has
less porosity compared to formulation prepared by batch process heat fusion. HME
process gave us stable and slower release compare to heat fusion. Formulations prepared
by heat fusion gave burst release. Our results in agreement with previous research group
(A. A. Obaidat & Obaidat, 2001). Stirring force is not as efficient as shearing force by
HME where DH can be completely embedded within the matrix as the same behavior in
tramadol HCL prepared by heat fusion method that gave burst release while in our case
with HME, it didn’t because of complete embedding via shearing force.
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3.4.7. Drug content and content uniformity
The conventional processed tablets have drug content and content uniformity variation
because inefficient drag flow inside the barrel, due to the low melt viscosity of lipid. This
makes the extrusion of the lipids a challenging process (J. Liu et al., 2001). Drug content
and tablet content uniformity were improved on extruding the formulation with MCC
(Figure 3-10). Drug content and tablet content uniformity analysis displayed that the drug
was uniformly distributed within the tablets with a standard deviation of <4%, indicating
a good formulation and process. The reason behind the improvements of drug content and
content uniformity is that the MCC plays a vital role in improving lipid followability as it
enhanced the drag flow and consistency of mixing inside the extruder barrel. Therefore,
there was a good dispersive and distributive effect of DH particles inside the lipid matrix.
The premixed MCC formulation exhibited a 102.4% drug content compared to those
without MCC, which was approximately 71.4%. (P value equals 0.0003, statistical
analysis using an unpaired t-test).

3.4.8. Mechanism of MCC behavior on drug release from tablet prepared by
conventional tableting method (i.e. not co processed MCC formulation)
MCC absorbed water into the tablet through capillaries, leading to swelling and
eventual disintegration of the tablets. New surfaces were thus created for drug diffusion
to occur. This finding is in agreement with El- Shanawany who reported a faster release
of nitrofurantoin from lipid tablets containing MCC (El-Shanawany, 1993).

55

3.4.9. In-vitro release study for the screened milled extrudates formulations
Lipid gave lubrication effect to EC N7 to decrease the processing temperature but
didn’t solve the burst release behavior of EC-N7. As shown in Figure 3-9, Formulation
(DH: Lipid: Mannitol 1:2:0.075) demonstrated sustained, stable and complete release in
10 hours. Dissolution test showed various release profiles as seen in Figure 3-7
(monophasic, biphasic release profiles) according to different carrier’s characteristics.
The addition of MNT enhanced the drug release due to its pore forming capability. Using
only a lipid as a carrier in the formulation resulted in a nearly ideal (zero-order) release
profile; however, the physical properties of the extruded material were not suitable for
further processing, such as tableting or capsule filling operations (i.e. in our case sticking
in capsules and tablet separation and capping while in dissolution and then result in a
faster and burst release). Film coating technique is the conventional solution to prevent
burst release, but in case of lipid, there is no need to do this technique. Burst release
phenomena could be solved by film coating but in our case, we solved the burst release
with HME lipid extrusion. Initial burst release from the matrix could probably be
attributed to the dissolution of drug from the surface of milled EXTs. This issue can be
solved via HME but only in the case of lipid not E-RS, nor EC-N7. The goal of adding
lipid in screening of polymers to decrease the extent initial burst release with other
formulations as shown in Figure 3-7. Also, to avoid dose dumping caused by food
agitation with other gel forming matrices (A. A. Obaidat & Obaidat, 2001; S. B. Tiwari,
Murthy, Raveendra Pai, Mehta, & Chowdary, 2003). The reason why E-RS provided
more sustained release because it is non-permeable polymer. Furthermore, the reason
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why excluding E-RS and EC-N7 because it is not consistent release profile (diphasic
release profile not monophasic release profile) and gave burst release during the first hrs.
In the last hrs., the release profile only increased slightly because it is below the
percolation threshed (Crowley et al., 2004) leading to incomplete drug release. This
phenomenon usually happens assumingly due to limited access of deeper drug particles to
the dissolution media since they are completely embedded in the hydrophobic EC-N7 and
E-RS. During the initial stage of the dissolution test, drug clusters located on the surface
of the granules were readily released into the dissolution medium. As the dissolution
process progressed, fewer drug clusters were accessible to the dissolution medium and a
plateau was reached (F. Zhang, 2016). This plateau behavior is because that it is under
the percolation threshold. Below the percolation threshold, incomplete drug release is
observed presumably due to limited accessibility of many drug particles to the dissolution
medium since they are encapsulated by water insoluble polymeric materials (Crowley et
al., 2004; F. Zhang, 2016).

3.4.10. Effect of varying processing temperature and lipid ratio on dissolution
profile of milled EXTs
The effect of extrusion temperature and C-888 ratio on release profile has been studied.
It has been confirmed in previous studies that the processing temperature played a
significant role in tortuosity of the carrier (Crowley et al., 2004; Frenning, 2011; J., P., &
I., 2006; Y.-E. Zhang & Schwartz, 2003). At processing temperature of the melting point
of the lipid and above (i.e. 74 ºC and above), formulations processed via HME did not
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give any fast release because of particles being on surface at the beginning which means
that because of shearing force and mixing and distributive and dispersive mixing player a
role in completely embedding the DH particles within the lipid matrix (Figure 3-8).

3.4.11. Dissolution studies of processed tablets
MCC works by swelling in water, and eventually, disintegration of the matrix like
what happened in conventional tablets. The release from all the tablets prepared was
studied under different pH values. It was observed that the release of DH from such
matrices is independent of the pH since the release rates were almost similar under the
studied pH values. This result was expected since DH is a salt of a basic drug with a pKa
of 8.2. Therefore, it is ionized over the pH range of interest and soluble at all pH values
used in this study, and it can be concluded that the matrix is inert towards changes in pH.
Presence of MCC which is hydrophilic polymer is not preferable for water soluble API,
but this could be solved by premixed co extrusion. Faster and less consistent release was
achieved from the conventionally prepared tablets comprising MCC and the structures
were observed to swell and split into layers laterally during dissolution testing, which was
ascribed to the nature of MCC promoting disintegration (Treanor, Roberts, Mostafa, &
Miolane, 2010). The addition of MNT enhanced the drug release due to its pore forming
capability. Formulation (DH: Lipid: Mannitol 1:2:0.075) demonstrated sustained, stable
and complete release in 10 hours.
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The premixed MCC formulation containing a mixture of DH, C- 888 ATO (1:2) and
microcrystalline cellulose, exhibited a more sustained drug release as compared to the
marketed Aricept® formulation. However, on increasing the drug ratio to (1:1), the drug
release is enhanced and reached up to 81% after 10 hrs. (Figure 3-11) compared to
control tablets (100% after 10 hrs). After 10 hrs in dissolution media, the premixed MCC
tablets remained intact with no cracks and this explains the lower drug release profile
compared to the marketed Aricept®. However, the conventional processed tablets
demonstrated cracks in the middle of tablets. This explains the faster release profile.
However, in the formulation of MNT (0.1), there is a burst release. The commercial
control utilized a film coating technique to achieve extended release behavior. f2Similarity factor between DH:Lipid (1:1) and control tablet is 54 (above than 50 means
similar profiles).

3.4.12. SEM analysis for carriers’ screening
Surface morphology was examined by SEM for all EXTs. As it can be seen in Figure
3-6, the pure drug crystals appeared to be irregular in shape and size as aggregates of
needle form i.e. microcrystalline aggregates with a coarse surface. DH: Lipid (1:2), DH:
Lipid: EC-N7 (1:1:1) and DH: EC-N7 (1:2) formulations showed the presence of DH in
the microcrystalline aggregate needle form, which is distinguishable from other
formulations. In case of EXTs of formulations of DH: EC-N7: MNT (1:2:0.1) and DH:
Eudragit® RS PO (1:2) it was clear that the aggregates disappeared meaning an
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amorphous DH within the hydrophobic matrices during the extrusion processing as it was
confirmed by DSC results. In other words, no aggregation has been noticed suggesting a
completely miscible single-phase binary solid dispersion system. SEM demonstrated that
the process enables active ingredients to be embedded into an insoluble matrix since there
is no any crystals on the surfaces but instead smooth surface.

3.5. Conclusion
DH can be formulated in a solvent free-one step- cost effective- continuous process
using C888 as a sustained release matrix with MNT as a hydrophilic pore former. It was
confirmed that DH in lipid matrix is immiscible and it preserve its crystallinity during
extrusion process. However, some fractions of DH are being solubilized in lipid matrix
with no endothermic peaks, whereas formulations with MNT hasn’t maintained its
crystallinity. The optimized formulation (DH: Lipid: Mannitol 1:2:0.075) demonstrated
sustained, stable and complete release in 10 hours. Furthermore, in-vivo investigations are
required to correlate with in-vitro dissolution studies for the development of optimum
oral sustained release matrix tablets of DH which is the scope of next future study. The
prepared tablets have shown good post compression characteristics regarding hardness,
friability, weight drug, content and content uniformity, and desired and reproducible drug
release profiles as compared to the reference commercial product. It has been concluded
from the dissolution profiles that HME technique can be utilized for the manufacture of
DH sustained release tablets by co processing of tablet excipients with API/C-888.
Tailoring the ratio of C-888 and MNT in the formulations, along with an appropriate
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extrusion temperature profile, resulted in modifying the release of DH and obtained the
preferable release pattern. Co extrusion of tablet excipient (MCC) with API/matrix
former could be a problem-solving approach for the development of lipid based
hydrophilic APIs. This could contribute in the reduction of processing steps such as
blending steps as well as improve the integrity of lipid-based tablets. HME processing
temperature profile plays key factor in the dissolution behavior of DH. It has been
demonstrated that co extrusion of tablets excipients within API/lipid matrix resulted in
different dissolution behavior and tablet properties. Although DH in amorphous form in
the case of formulation that contains hydrophilic diluents/fillers such as MNT and MCC,
the release was sustained and stable. The only explanation is that these hydrophilic
excipients are embedded within C-888 matrix. This new insight gives a new trend in
terms of preparing a developed continuous tableting process (e.g. mini matrices) in solid
lipid extrusion field. This insight would give useful information in terms of product
development.
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Table 3-1: Formulation compositions and processing parameters for lipid carrier
DH (ratio
w/w)
1
1

C-888 (ratio
w/w)
4
3

MNT (ratio
Screw
Zone/Temp.
w/w)
Speed
N/A
N/A
Zone 2-3-4: 68 ºC
Zone 5-6-7: 74 ºC
50/100 rpm
N/A or 0.1 or
1*
2*
Zone 8-9-10&die: 68 ºC
0.075
1
1
N/A
*(1:2) (DH:C-888): Also, processed by conventional heat fusion method at processing
temperature 100 ºC.

Table 3-2: Formulation compositions and processing parameters for EC-N7
with/without lipid carrier

DH (ratio
w/w)

EC N7(ratio w/w)

C-888
(ratio w/w)

MNT
(ratio w/w)

1
1
1
1

4
3
2
1

N/A
N/A
N/A
N/A

N/A
N/A
0.1
N/A

Stearic
Acid
(ratio
w/w)
0.05
0.05
0.05
0.05

1

1

1

N/A

N/A

Zone/Temp.

All zones:
140 ºC

Screw
Speed

100
rpm

All zones:
100 ºC

Table 3-3: Formulation compositions and processing parameters for E-RS carrier
DH
(ratio
w/w)
1
1
1
1

Eudragit® RS PO (ratio
w/w)
4
3
2
1

Zone/Temp.

All zones: 150 ºC
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Screw Speed

100 rpm

Table 3-4: HME processing conditions to study effect of HME processing
temperature on lipid-based formulations drug release profile
HME Parameters
Barrel Temperature Profiles (ºC)
Screw Speed (rpm)

Processing Conditions
Zone 2-7: 77 ºC, Zone 8-10 & Die: 70 ºC
Zone 2-7: 75 ºC, Zone 8-10 & Die: 70 ºC
All zones: 70 ºC
50 rpm

Table 3-5: Tablet compositions for conventional processed Tablets 300 mg tablet
weight
33.33% DH/C-888 EXTs

50% DH/C-888 EXTs

Weight

Weight

Material
%(W/W)

%(W/W)
(mg/tablet)

(mg/tablet)

DH

8

23

7.67

23

C-888

16

46

7.67

23

75

228

83.66

251

Magnesium Stearate

1

3

1

3

Total

100

300

100

300

Avicel® PH 102
(MCC)
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Table 3-6: Tablet compositions for conventional processed Tablets 200 mg tablet
weight
33.33% DH/C-888 EXTs
Material

50% DH/C-888 EXTs

Weight
%(W/W)

Weight
%(W/W)

(mg/tablet)

(mg/tablet)

DH

11.5

23

11.5

23

C-888

23

46

11.5

23

Avicel® PH 102 (MCC) *

64.5

129

76

152

Magnesium Stearate

1

2

1

2

Total

100

200

100

200

* Also, co-processed while extruding the formulation
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Figure 3-1: DH/C-888 and DH/C-888/MNT DSC studies performed at
temperatures of 30-250 °C and heating rate of 20 °C/min.
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Figure 3-2: DH/C-888 DSC studies performed at temperatures of 30-250 °C and
heating rate of 20 °C/min.
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Figure 3-3: DH/C-888/EC-N7(1:1:1) and DH/EC-N7(1:2) DSC studies performed
at temperatures of 30-250 °C and heating rate of 20 °C/min.
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Figure 3-4: DH/Eudragit® RS PO (1:2) and DH/EC-N7/MNT (1:2:0.1) DSC
studies performed at temperatures of 30-250 °C and heating rate of 20 °C/min.
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Figure 3-5: Formulation strand digital pictures
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Figure 3-6: SEM of pure DH and screened extrudates
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Figure 3-7: In-vitro drug release of Donepezil HCl
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Figure 3-8: Effect of HME processing temperatures on the
in-vitro release (DH: Lipid 1:2)
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Figure 3-9: In-vitro drug release of Donepezil HCl
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Figure 3-10: Drug content of DH tablets
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Figure 3-11: In-vitro drug release of optimized DH tablets
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CHAPTER 4:
CONCLUSIONS
In the current research work, an attempt has been devised to enhance drug
bioavailability and the therapeutic efficacy, reduce the drug administration frequency and
improve patient compliance by developing a floating matrix mini tablet of APAP as well
as to investigate the processed low-density polymers with regard to their high porosity
and resultant floating efficiency. P-CO2 melt EXTs were successfully achieved using
Eudragit® RS PO, Eudragit® RL PO, and Ethyl Cellulose EC-N7, with foamy and/or
porous matrices. P-CO2/HME demonstrated promising in-vitro buoyancy efficiency and
sustained release profiles. A comparison study with conventional method for preparing
floating system has been done to test the efficiency of this proposed approach. Using this
combined technology (P-CO2/HME), low-density floating devices can be designed and
developed for other APIs/polymers. It overcomes the existing limitations commonly
associated with other conventional techniques for manufacturing floating solid dosage
forms. This study gives an important insight into combining HME/P-CO2 continuous and
scalable technology for the development of floating devices, which may be useful for the
large-scale production. In addition, it has been confirmed that DH extrudates with up to
50% drug loading can be processed with C-888 maintaining the sustain release behavior
and drug crystallinity even though with a highly soluble drug. Based on the initial
screening studies and findings, C-888 were chosen as the main carrier for further
76

investigations to prepare DH tablet. Highly water-soluble drugs such as DH can be
prepared as a sustained release formulation, with improved drug content and content
uniformity while maintaining the drug’s crystallinity, using a twin-screw extrusion
process employing the extrusion of premixed microcrystalline cellulose embedded within
a hydrophobic matrix and a relatively low processing temperature profile. Tailoring the
ratio of C- 888 ATO and MCC in the formulations, along with an appropriate extrusion
temperature profile, can be utilized to modify the release of DH. Finally, the release
profile of the optimized formulation of DH was similar to the marketed formulation with
f2 above than 50.
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